Aclarubicin (ACLA), which belongs to the antracycline class of antineoplasic agents, has been demonstrated as a differentiating agent for a broad range of human solid tumors and leukemia. By using dihydroethidium as a fluorescent probe, we show the ability of subtoxic (i.e. differentiating) concentration of ACLA to generate reactive oxygen species in both K562 and HL-60 leukemia cell lines. Besides, we have used a calcein-based spectrofluorimetric assay to determine the influence of ACLA-treatement on the cellular labile iron pool (LIP). In both cell lines, the LIP level was markedly decreased in the presence of ACLA. Nevertheless, whereas ACLA-induced differentiation was obviously ROS-dependent, the LIP decrease was rather ROSindependent.
Introduction
Aclarubicin (ACLA) belongs to the anthracycline class of antineoplasic agents widely used in conventional cancer chemotherapy of solid tumor and leukemia [1] .
While anthracyclines cytotoxic effects are commonly accepted to be due to DNAintercalation and interaction with the nuclear enzymes DNA-topoisomerases [2] , additional targets have been proposed such as alteration of the mitochondrial function [3] , and production of free radicals [4] [5] [6] . In addition, numerous in vitro and in vivo studies have demonstrated that anthracycline, when used at subtoxic concentrations, are potent differentiation inducers of solid tumors and leukemia [7, 8] . Particularly, ACLA induces differentiation of K562 and HL-60 human leukemic cell lines [8, 9] . It should be noticed that the subtoxic concentration of ACLA used in differentiation studies was 50-200 times lower than the plasmatic concentration found in patients [10] .
The ability of anthracyclines to produce free radicals, or reactive oxygen species (ROS), in cells or tissues has been demonstrated with high doses of doxorubicin, as commonly used in chemotherapy [4] [5] [6] . Then, oxidative damages consecutive to anthracycline treatment has been though to explain the high cardiotoxicity of these drugs [11, 12] . Furthermore, our recent studies have suggested the involvement of oxidative stress in the anthracycline-triggered differentiation of leukemic cells. In these studies, subtoxic concentrations of ACLA were used to induce the erythroid differentiation of the human K562 cell line, and antioxidants were shown to inhibit the ACLA effect [13] . These results supported the involvement of ROS production in the mechanism of action of ACLA, even at very low concentration.
The same redox properties that allow iron to be a functional enzymatic cofactor also make this metal a key participant in oxygen-mediated toxicity as a catalysor of the Fenton reaction [14] . Then, a role for iron has been suggested in the cardiotoxicity of hal-00422915, version 1 -8 Oct 2009 anthracyclines and the influence of iron addition or depletion on anthracycline effects has been investigated [15] . In addition, a putative effect of anthracycline on iron metabolism has been recently questioned [16] .
All aspects of intracellular iron homeostasis are mirrored in the so-called labile iron pool (LIP), a low-molecular-weight pool of weakly chelated iron that rapidly transits through the cell and constitutes a real crossroads of metabolic pathways of ironcontaining compounds. It has been claimed that LIP is a cellular source of iron participating in the Fenton reaction [17] as well as a sensor for the iron responsive element (IRE) -iron regulatory protein (IRP) system [18, 19] . It seems that under physiologic conditions, a constitutive level of LIP is midway between the cellular need for iron and the hazard of excessive generation of OH radical, the most potent oxidant encountered in biological systems. Any depletion or rise in the LIP may result either in impairment of synthesis of iron-containing proteins or in cell injury by pro-oxidants, as this has been clearly demonstrated in erythroid cells overexpressing H-ferritin [20] or exposed to transferrin [17] .
Therefore, we intended here to compare the production of ROS in both K562
and HL-60 cell lines treated with subtoxic concentration of ACLA, and to determine the effect of ACLA on intracellular LIP level. By using spectrofluorimetric assays, we show that ACLA induces ROS generation and a decrease of LIP in both K562 and HL-60 leukemia cell lines. Nevertheless, whereas ACLA-induced differentiation was ROSdependent, the LIP was rather ROS independent. hal-00422915, version 1 -8 Oct 2009
Materials and methods

Chemicals
Culture medium (RPMI-1640 with Glutamax) and fetal bovine serum were from Life Technologies (Saint-Quentin-en-Yvelines, France). Calcein-acetoxy-methyl-ester (Calcein-AM) was purchased from Molecular Probes (Eugene, OR). All other chemicals, including the fluorescent probe dihydroethidium, N-acetylcysteine (NAC), pyrrolidine-dithiocarbamate (PDTC) and ACLA were purchased from Sigma (L'Isled'Abeau-Chesnes, France).
Cell culture and induction of differentiation
The K562 and HL-60 cell lines were cultured in RPMI-1640 medium with Glutamax supplemented with heat-inactivated fetal bovine serum (10% and 15%, respectively), in a 5% CO 2 
Spectrofluorimetric determination of LIP
LIP was determined by spectrofluorimetry as previously described [17] with slight modifications. Briefly, after indicated treatment, 2.10 6 cells were resuspended in 2 ml prewarmed buffer (20 mM HEPES, pH 7.3, 150 mM NaCl, 1% bovine serum albumin), and were incubated with 50 nM calcein-AM for 15 min at 37°C. After centrifugation and washing, cells were resuspended in the same buffer, and the calcein fluorescence intensity was recorded as a function of time. A stable baseline signal was recorded for 60 sec before the addition of 100 µM SIH, a highly permeant iron chelator, which caused a rise in fluorescence corresponding to the level of LIP. Calibration and calculation of LIP concentration were made as described by Epsztejn et al. [17] . The excitation and the maximal emission wavelengths were 483 nm and 505 nm, respectively.
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Results
Differentiating effect of ACLA
A subtoxic concentration of ACLA (25 nM) induced erythroid and granulocytic differentiation of K562 and HL-60 cell lines, respectively. In both cases, maximal differentiation was achieved within 3 days with a marked growth inhibition but without cytotoxicity (Table 1) . Although a long term exposure to 25 nM ACLA (i.e. 72 h) was more convenient, the exposure period could be reduced to 24 h without affecting the percentage of differentiated cells at day 3 (data not shown). Furthermore, a 1 h pulse with a ten fold higher concentration of ACLA (250 nM) was sufficient to induce significant differentiation of K562 and HL-60 cells (Table 2 ). These results indicated that the differentiation process was engaged irreversibly in the first hour of ACLA treatment.
In addition, differentiation was markedly inhibited by the presence of antioxidants (either NAC or PDTC) during the 1 h pulse of ACLA (Table 2) , suggesting the involvement of ROS as a signal for ACLA-induced differentiation.
ACLA-triggered ROS production
Whether ACLA induced oxidative stress was investigated by using the fluorescent probe dihydroethidium. ACLA-treated cells were then incubated in the presence of 2 µM dihydroethidium for 10 min and analysed by spectrofluorimetry. Into the cells, the blue fluorescence (λ em 420 nm) of dihydroethidium probe is shifted to red (λ em 640 nm) when oxidized in the presence of ROS. Then, the 640 nm / 420 nm fluorescence intensity ratio permits to evaluate the production of ROS in cells, and allow a comparison between the two cell lines. As evidenced by the increased fluorescence intensity ratio, ROS production was observed in both K562 and HL-60
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cell lines after one hour of treatment with 25 nM ACLA (Fig. 1) . Nevertheless, this ROS production was higher in the K562 cell line (Fig. 1) . The fluorescence intensity ratio diminished in the case of longer ACLA-treatment, suggesting that ROS production occurred in the first hour of ACLA-treatment and then declined with time (data not shown).
ACLA-induced decrease of LIP level
The incidence of subtoxic ACLA-treatment on LIP level was investigated in K562 and HL-60 cell lines by using a calcein-based spectrofluorimetric assay. Despite LIP level was about 2.5 fold higher in the K562 pre-erythroid cell line ( Fig. 2A ) than in the HL-60 cells (Fig. 2B) , the results depicted in Figure 2 indicates that treatment with 25 nM ACLA for 18 h strongly reduced the LIP level in both cell lines. Nevertheless, the ACLA-induced LIP decrease was more marked in the HL-60 cell line (60% of decrease) than in K562 cells (31%) after 18h of incubation. This ACLA-mediated LIP decrease could be observed as soon as 8 h after ACLA-treatement but in a lesser extent (27% and 18% of decrease in HL-60 and K562 cells, respectively). Furthermore, the presence of the antioxidant NAC during the 18 h of ACLA treatment did not affect the reduction of LIP (Fig. 2) . In both cell lines, the extent of 25 nM ACLA effect was roughly the same as did the well known iron chelator deferoxamine at the concentration of 150 µM, suggesting that ACLA is a potent iron depletory agent (Fig. 2) . hal-00422915, version 1 -8 Oct 2009
Discussion
It is now well established that several anticancer drugs, among which the anthracyclines ACLA and doxorubicin, are metabolically activated to free radical states (semi-quinone). These species are themselves very reactive and interact with molecular oxygen to generate partially reduced oxygen species (superoxide, hydrogen peroxide and hydroxyl radical) [4] [5] [6] . In the case of doxorubicin, the involvement of iron in these processes was demonstrated [21] . In turn, the species produced are able to interact with the antioxidant defense systems [22] and a decrease in intracellular enzymes activities (superoxide dismutase, catalase, glutathion reductase or glutathion peroxidase) and in reduced glutathion level after DOX treatment was previously reported [23, 24] .
Our present results obviously indicate that ACLA-induced differentiation was dependent from ROS production. This further support previous data obtained in the K562 and HL-60 cell lines with various inducers, including anthracyclines, butyric acid, Ara-C, ADP-Fe 2+ and H 2 O 2 [13, 25, 26] . In the present case of ACLA-induced differentiation, such a ROS generation will probably stimulates gene specific expression through redox sensitive transcription factors (NF-κB, AP-1, NF-E2…), the involvement of which has already been demonstrated, at least in the erythroid differentiation of K562 cells [13] .
Iron metabolism is often linked with ROS production, therefore it appeared important to evaluate the influence of anthracycline treatment on the intracellular iron metabolism, and particularly the LIP level. Our present results clearly show that LIP was decreased in ACLA-treated cells. Nevertheless, the ACLA-induced fall of LIP appeared to be independent of ROS production. The fact that NAC did not prevent the LIP decrease whereas it efficiently reduced cell differentiation suggest that LIP decrease was not a consequence of ACLA-induced differentiation. By contrast, the
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ACLA-induced decrease of LIP could rather be thought as a cause of differentiation.
Indeed, a role for iron in the monocytic differentiation has been recently reported [27, 28] .
The ability of anthracyclines to irreversibly chelate iron could explain the decrease of LIP (and the production of ROS) [29] . In addition, the anthracycline doxorubicin (DOX) has been very recently reported to modulate the activity of iron regulatory proteins (IRPs). From one hand, the alcohol metabolite of DOX converted the cytoplasmic aconitase into its RNA binding form IRP-1 [30] . From the other hand, DOX produce ROS which inactivate both IRP-1 and IRP-2 [31] . But the consequences of the modulation of IRPs by DOX has not been assessed at the level of LIP. Then, elucidating the exact mechanism by which ACLA affects LIP level requires further investigations.
In view of our biological findings, clinical trials which associate ACLA, especially at very low dose, with other therapeutic treatment (chemotherapeutic agents or ionising radiation) should continue to be proposed. Indeed, nanomolar concentrations of aclarubicin are able to enhance the differentiation effect induced by 1µM doxorubicin in leukemic cells [32] . Enhancement of radiation-induced cell killing and DNA double-strand breaks in human colon tumour cells was also observed in presence of nanomolar concentrations of ACLA [33] . Another study from the same group has demonstrated that repair of radiation-induced DNA double-strand breaks decreased with cellular differentiation [34] . Taking into account that ROS production is induced by subtoxic doses of ACLA, we can suggest that ROS should enhance radiationinduced DNA double-strand breaks via induction of cellular differentiation. In addition, the LIP decrease we described here could serve as an additional explanation for the antiproliferative and pro-apoptotic effects of ACLA. Indeed, iron depletion has been reported to inhibit DNA synthesis at the level of ribonucleotide reductase [35] and,
apoptosis has been observed in response to a decrease of intracellular iron level and in synergy with anticancer drug [36] [37] [38] . By contrast, the addition of hemin has a protective effect against DOX-induced apoptosis [39] .
To conclude, the use of very low dose of ACLA should reduced its cardiotoxicity and nevertheless allowed its antiproliferative and pro-apoptotic effects probably through ROS production and LIP decrease. 
